---
title: "IFF: Strong H1 2026 growth, robust cash flow, and major divestiture to fund debt reduction and buybacks"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294965437.md"
description: "First half 2026 saw 4% sales and 8% profitability growth, with strong cash flow and improved working capital. The Food Ingredients segment divestiture will fund debt reduction and a $2.5B share repurchase. FY 2026 guidance anticipates continued growth and margin expansion.Original document: International Flavors & Fragrances, Inc. [IFF] Slides Release — Aug. 5 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-05T12:13:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294965437.md)
  - [en](https://longbridge.com/en/news/294965437.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294965437.md)
generator: "portal-rs"
---

# IFF: Strong H1 2026 growth, robust cash flow, and major divestiture to fund debt reduction and buybacks

First half 2026 saw 4% sales and 8% profitability growth, with strong cash flow and improved working capital. The Food Ingredients segment divestiture will fund debt reduction and a $2.5B share repurchase. FY 2026 guidance anticipates continued growth and margin expansion.

Original document: International Flavors & Fragrances, Inc. \[IFF\] Slides Release — Aug. 5 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [IFF.US](https://longbridge.com/en/quote/IFF.US.md)

## Related News & Research

- [IFF President, Scent Ana Paula Teles de Mendonca disposes of $475,293 common shares](https://longbridge.com/en/news/296361330.md)
- [IFF Report Finds GLP-1 Is Reshaping Food Choices and Eating Behaviors Among Indian Consumers | IFF Stock News](https://longbridge.com/en/news/296863572.md)
- [SoftwareOne attaches full H1 2026 report in correction to earlier release](https://longbridge.com/en/news/297010247.md)
- [Cemat publishes H1 2026 interim report](https://longbridge.com/en/news/297006906.md)
- [EGTX: Q2 2026 revenue up 23% YoY; U.S. Emcitate launch expected Q4 2026 pending FDA approval](https://longbridge.com/en/news/296636890.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**